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ABSTRACT Vaginal inflammation (vaginitis) is the most common disease caused by the human-pathogenic fungus Candida al-
bicans. Secretory aspartyl proteinases (Sap) are major virulence traits of C. albicans that have been suggested to play a role in
vaginitis. To dissect the mechanisms by which Sap play this role, Sap2, a dominantly expressed member of the Sap family and a
putative constituent of an anti-Candida vaccine, was used. Injection of full-length Sap2 into the mouse vagina caused local neu-
trophil influx and accumulation of the inflammasome-dependent interleukin-1 (IL-1) but not of inflammasome-independent
tumor necrosis factor alpha. Sap2 could be replaced by other Sap, while no inflammation was induced by the vaccine antigen, the
N-terminal-truncated, enzymatically inactive tSap2. Anti-Sap2 antibodies, in particular Fab from a human combinatorial anti-
body library, inhibited or abolished the inflammatory response, provided the antibodies were able, like the Sap inhibitor Pepsta-
tin A, to inhibit Sap enzyme activity. The same antibodies and Pepstatin A also inhibited neutrophil influx and cytokine produc-
tion stimulated by C. albicans intravaginal injection, and a mutant strain lacking SAP1, SAP2, and SAP3was unable to cause
vaginal inflammation. Sap2 induced expression of activated caspase-1 in murine and human vaginal epithelial cells. Caspase-1
inhibition downregulated IL-1 and IL-18 production by vaginal epithelial cells, and blockade of the IL-1 receptor strongly
reduced neutrophil influx. Overall, the data suggest that some Sap, particularly Sap2, are proinflammatory proteins in vivo and
can mediate the inflammasome-dependent, acute inflammatory response of vaginal epithelial cells to C. albicans. These findings
support the notion that vaccine-induced or passively administered anti-Sap antibodies could contribute to control vaginitis.
IMPORTANCE Candidal vaginitis is an acute inflammatory disease that affects many women of fertile age, with no definitive cure
and, in its recurrent forms, causing true devastation of quality of life. Unraveling the fungal factors causing inflammation is im-
portant to be able to devise novel tools to fight the disease. In an experimental murine model, we have discovered that aspartyl
proteinases, particularly Sap2, may cause the same inflammatory signs of vaginitis caused by the fungus and that anti-Sap anti-
bodies and the protease inhibitor Pepstatin A almost equally inhibit Sap- and C. albicans-induced inflammation. Sap-induced
vaginitis is an early event during vaginal infection, is uncoupled from fungal growth, and requires Sap and caspase-1 enzymatic
activities to occur, suggesting that Sap or products of Sap activity activate an inflammasome sensor of epithelial cells. Our data
support the notion that anti-Sap antibodies could help control the essence of candidal vaginitis, i.e., the inflammatory response.
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Secretory aspartyl proteinases (Sap) of Candida albicans areconsidered to play important roles in the pathogenicity of this
fungus. They constitute a family of at least 10 members with sub-
families, for instance, Sap1-3 and Sap4-6, each characterized by
close homology and physiological relevance. Various lines of evi-
dence have suggested that Sap expression enables the fungus to
adhere and/or invade and damage host tissues and, perhaps more
importantly, cause deviations in, if not exacerbate, host immunity
(1–3). Although SAP gene expression studies and experimental
systemic C. albicans infections with SAP-deleted mutants have
generated some contradictory findings (4, 5), the pathological sig-
nificance of Sap production by this fungus in mucosal infections
rests upon rather consistent experimental and clinical evidence
(6–8). In particular, Sap2 is a dominant member of the Sap family
that is secreted at high levels in the vaginas of experimentally in-
fected rats and in women affected by vulvovaginal candidiasis
(VVC) (7, 8). Antibodies (Abs) against Sap2 are protective against
experimental vaginal infection in estrogen-treated rats (9, 10). A
virosomal preparation of a recombinant, enzymatically inactive
Sap2 has been shown to confer protection in the above model and
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has been proposed as a vaccine against recurrent vaginal candidi-
asis (11). However, little is known about the mechanisms whereby
Sap2 and other Sap contribute to the pathogenesis of vaginal can-
didiasis, and the mechanisms enabling anti-Sap immune re-
sponses to control vaginal candidiasis in experimental models are
unclear.
Recent investigations by our group have shown that Sap2 (and
other members of the Sap family) can induce an inflammatory
response by human monocytes, macrophages, and dendritic cells
in vitro, likely through activation of NLRP3 inflammasome and
induction of different caspases (12, 13). However, it is unknown
whether Sap exert proinflammatory activity in vivo and whether
neutralization of this activity is relevant for protection against
vaginal candidiasis, a disease characterized by typical signs and
symptoms of acute inflammation (14–17).
To elucidate the mechanisms by which Sap cause vaginal in-
flammation in vivo, we used two recombinant forms of Sap2, one
with an N-terminal-truncated, enzymatically inactive protein
(tSap2, i.e., the antigenic constituent of the virosomal vaccine)
and the other a full-length protein with preserved enzymatic ac-
tivity (Sap2). Both proteins were directly injected into the vaginal
cavity of mice under conditions that are predisposing to C. albi-
cans infection (estrogen treatment) and at concentrations in the
range of those found both in the vagina of experimentally infected
rats and in the vaginal cavity of naturally infected women (8, 10).
Other Sap were also tested and/or used as controls. We observed
the mice for two classical signs of inflammation and inflam-
masome activation: polymorphonuclear cells (PMN, neutrophil)
influx and the presence of cytokines, particularly interleukin-1
(IL-1), in the vaginal fluid of mice. We also asked whether Sap2
and other Sap could be directly involved in the vaginal inflamma-
tion caused by C. albicans in our mouse model. We observed that
the vaccine antigen tSap2 was devoid of proinflammatory activity
in the mouse vagina and that anti-tSap2 Abs and Pepstatin A, a
protease inhibitor known to inhibit Sap, were able to markedly
reduce or abolish the inflammatory activity of the full-length Sap2
as well as the vaginal inflammation caused by C. albicans.
RESULTS
Proinflammatory activity of Sap2, but not tSap2, in the mouse
vaginal cavity. In previous studies, we found relatively high con-
centrations of Sap2 in the vaginal fluid of rats experimentally in-
fected with C. albicans and in women with acute, recurrent vagi-
nitis (in some subjects, concentrations even higher than 500 ng/ml
in vaginal fluid were found) (7–9). Moreover, anti-Sap2 Abs con-
ferred protection against experimental vaginal candidiasis, lead-
ing to the proposal of a Sap2-based anticandidal vaccine (3, 11).
For these reasons and the availability of both a full-length, enzy-
matically very active recombinant Sap2 and a truncated, enzymat-
ically inactive tSap2 as an appropriate control (see below; see also
Fig. S1A in the supplemental material), we tested active and tSap2
versions for their capacities to induce vaginal inflammation (vag-
initis) in mice. Following dose-finding experiments (data not
shown), doses of 0.5g Sap2 and tSap2 were found to be optimal.
Sap2 or tSap2 was directly injected into the mouse vaginal cavity,
and vaginal fluid was harvested 24 h later and examined for num-
bers of GR-1-positive cells (PMN) and IL-1 concentrations. As a
comparator and nonspecific marker of inflammation, lipopoly-
saccharide (LPS; 50 g) was injected into the vaginal cavity of
other mice (positive control), whereas mice injected with saline
only served as negative controls. Figure 1 shows the cumulative
data of all mice tested. Despite the expected variability, the graphs
show that both Sap2 and LPS, but not tSap2, were capable of
inducing a marked influx of PMN and IL-1 production in the
mouse vagina compared to saline-injected mice. Based on these
results, tSap2 was further used as a suitable negative control,
whenever appropriate. In addition, we assayed for the presence of
tumor necrosis factor alpha (TNF-) upon intravaginal injection
of Sap2 or LPS. Elevated levels of this cytokine were found follow-
ing LPS stimulation, but it was not detected upon Sap2 stimula-
tion (see Fig. S1B). Of note, the most active Sap2 concentration
used in the above-described experiments fell in the range of Sap2
levels found in rats experimentally infected with C. albicans
and those in clinical samples from women with candidal vagi-
nitis (7, 8).
We also tested other recombinant Sap, in dose-response exper-
iments (data not shown), to examine their capacity to induce vag-
FIG 1 Proinflammatory activity of Sap2 in the mouse vaginal cavity. Dot plot
graphs of the percentage of GR-1-positive cells (PMN) (upper panel) or IL-1
production (lower panel) from vaginal washes of mice after 24 h of intravagi-
nal injection of saline, LPS (50 g/10 l/mouse), or Sap2 or tSap2 (both at
0.5g/10l/mouse). *,P 0.01 for LPS- or Sap2-treated versus saline-treated
mice; #, differences between LPS- and Sap2-treated animals were not statisti-
cally significant.
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inal inflammation. As also expected from Sap protein homology
(1) and published data on monocyte inflammatory responses in
vitro (12, 18), other Sap, in particular Sap1, Sap3, and Sap6, were
shown to activate a similar response, but none of these proteinases
caused a stimulation which was superior to the inflammation in-
duced by Sap2 at doses compatible with those found in vivo (7, 8)
(see Fig. S2 in the supplemental material).
Specificity of Sap2-induced vaginal inflammation and its in-
hibitionbySap2binders.Anti-Sap neutralizing Abs, induced by a
virosomal, tSap2-based vaccine, have been suggested to be re-
sponsible for a protective response in a rat vaginitis model (6, 11).
Thus, we wondered whether anti-Sap2 Abs, raised in rabbits im-
munized with the above vaccine, could directly inhibit Sap2-
induced vaginal inflammation in mice. We also controlled for
specificity of this serum by testing its effect on LPS-induced in-
flammation, and we used nonimmune serum as a negative con-
trol.
As shown in Fig. 2A and B, nonimmune and immune rabbit
sera were unable to cause significant PMN influx or IL-1 pro-
duction over the saline background in nontreated mice. In con-
trast, the immune serum caused significant inhibition of Sap2-
stimulated PMN influx and IL-1 production, with no significant
effect on stimulation by LPS. Since the serum may contain non-
specific Sap2 inhibitors that could be enriched in immune serum,
more specific evidence was sought via the use of monoclonal Abs
(MAbs). The Fab format was selected to avoid any potential inter-
ference due to Ab binding to Fc receptors of cells present in or
recruited into the vaginal cavity. Two of these latter Abs were
selected, one capable of binding Sap2 and inhibiting its enzymatic
activity (HuCal I) and another one equally capable of Sap2 bind-
ing but unable to inhibit its enzymatic activity (HuCal nI). As
shown in Fig. 2C and D, neither compound showed proinflam-
matory activity in itself; however, HuCal I nearly abolished Sap2-
induced PMN influx (Fig. 2C) and significantly inhibited IL-1
production (Fig. 2D). On the contrary, HuCal nI caused a nonsig-
nificant reduction of PMN influx and minor effects on IL-1 pro-
duction.
Both tSap2’s inability to cause inflammation and the marked
difference between HuCal I and HuCal nI Fab suggested a critical
role exerted by Sap2 enzymatic activity in the inflammation.
FIG 2 Effect of immune serum, HuCal Abs, and Pepstatin A on Sap2 proinflammatory activity. Vaginal washes of mice treated for 24 h with saline, LPS
(50 g/10 l/mouse), or Sap2 (0.5 g/10 l/mouse) in the presence or absence of nonimmune serum, immune serum, noninhibitory or inhibitory (HuCal nI
or HuCal I) MAb, or Pepstatin A were analyzed for the percentage of GR-1-positive cells (A and C) or IL-1 production (B and D). Data are expressed as means
 SEM. *, P 0.05 LPS- or Sap2-treated versus saline-treated mice; #, P 0.05 for immune serum, HuCal I, or Pepstatin A plus Sap2 treatment, versus Sap2
treatment.
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Thus, we tested the effect of Pepstatin A, a well-known inhibi-
tor of aspartyl proteinase activity. Data in Fig. 2C and D show
that Pepstatin A had roughly the same inhibitory effects as the
HuCal I Fab in decreasing PMN influx and cytokine production
compared to the saline background. Neither HuCal I nor Pepsta-
tin A inhibited LPS-induced inflammation (data not shown). To-
gether with the data of the previous section, the results of these
experiments suggest that proinflammatory Sap2 activity at the
vaginal level is specific and requires functional enzymatic activity
to cause inflammation. These data also suggest that the inability of
some Sap (see Fig. S2 in the supplemental material) to cause vag-
inal inflammation could also be due to their low level of enzymatic
activity or different specificities in the vaginal environment.
Sap and vaginal inflammation caused by C. albicans. C. albi-
cans cells, particularly in their hyphal morphological form, cause
inflammation through inflammasome activation (19, 20), and
this inflammatory response is currently considered the main
pathogenic mechanism of experimental vaginal candidiasis in
mice (19, 20). Given that Sap2 is largely secreted during vaginal
infections, in both some experimental models and women (21),
we first asked whether and to what extent the fungal cells caused
inflammation in our experimental model, and also whether the
Sap2 inhibitors shown in the previous section could also inhibit
C. albicans-induced vaginal inflammation. To this aim, estrog-
enized mice were treated with anti-Sap2 immune serum or
Pepstatin A or enzyme-inhibitory HuCal I and then challenged
intravaginally with live C. albicans cells. The saline, nonimmune
serum, and HuCal nI groups served as controls. Twenty-
four hours after challenge, all mice were examined for neutrophils
and IL-1 content in the vaginal fluid. As shown in Fig. 3A and B,
the fungal cells (strain CA-6) induced marked PMN influx (Fig.
3A) and high IL-1 production (Fig. 3B), and these responses
were nearly abolished (PMN) or strongly inhibited (the cytokine)
by treatment with the anti-Sap2 immune serum or HuCal I or
Pepstatin A. Some reduction of both PMN influx and IL-1 was
also measured with nonimmune serum or HuCal nI, but this low-
ering did not reach statistical significance. We also examined
whether the blockade of the IL-1 receptor was affected by C. al-
bicans-induced neutrophil influx. As shown in Table 1, the block-
ade of IL-1 receptor, while obviously not affecting production
of IL-1, inhibited in a dose-dependent manner the PMN influx
in the mouse vagina, strengthening the functional role of
inflammasome-dependent cytokine production in our model.
Since (i) the inflammatory potential of Sap2 appeared to be
shared, at least in part, by its close homologs Sap1 and Sap3 (see
Fig. S2 in the supplemental material); (ii) both the immune serum
and the HuCal I Ab also recognized Sap1 and Sap3 in addition to
Sap2 (11) (data not shown), we next examined whether mutant
strains of C. albicans with deletion of one or all three of the SAP1,
SAP2, and SAP3 genes could retain the capacity to induce vaginal
inflammation. In these experiments, the strain CAI4 (SC5314 ge-
netic background), from which the SAP-deleted mutants were
FIG 3 Effects of immune serum, HuCal I, and Pepstatin A on vaginal inflammation induced by C. albicans (A and B) and on PMN influx in mice challenged
with sap and control strains (C). Vaginal washes of mice treated for 24 h with saline or CA-6 (2 107 yeast cells/10 l/mouse) in the presence or absence of
nonimmune serum, immune serum, HuCal nI, HuCal I, or Pepstatin A were analyzed for the percentage of GR-1-positive cells (A) or IL-1 production (B). (C)
PMN influx (percentage of GR-1 positive cells) of vaginal washes of mice challenged with CA-6, CAI4, or sap strains (2 107 yeast cells/10 l/mouse). In all
panels, data are expressed as means SEM. *, P 0.05 for CA-6 or CAI4- or sap-treated versus saline-treated mice; #, P 0.05 for immune serum, HuCal I,
or Pepstatin A plus CA-6 treatment versus CA-6 treated mice (for bar graphs including these treatment groups); #, P 0.05 for sap1 sap2 sap3 (sap1-3)-
treated mice versus CAI4-treated mice (where these treatments groups are indicated in bar graphs).
TABLE 1 Effects of anakinra on CA-6-induced vaginal inflammation
Endpoint
Treatmenta
Saline CA-6 CA-6 Anak at 1 M CA-6 Anak at 10 M CA-6 Anak at 100 M
% GR-1-positive cells 5.61 3.11 35.85 6.83 59.42 3.66 13.38 3.77 6.63 1.68
IL-1 (pg/ml) 24.36 8.99 257.70 91.30 176.9 27.89 167.0 37.29 170.66 32.60
a Vaginal washes from groups of six mice after 24 h of CA-6 challenge (2 107 yeast cells /10 l/mouse) in the presence or absence of the indicated concentration of anakinra were
analyzed for the percentage of GR-1-positive cells or IL-1 production. Saline-treated mice were used as controls. Data are expressed as means SEM.
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derived, was used as a positive control. Figure 3C shows that the
deletion of single SAP genes did not abolish the inflammatory
properties of the fungus and caused a slight, statistically not sig-
nificant, reduction of neutrophil influx into the vaginal cavity
compared to the parental strain. Only the deletion of all three
genes caused complete loss of PMN influx, with values similar to
those of the negative, saline-only injected control. The same data
were obtained with the production of IL-1 (15.4 7.8, 153.3
22.9, and 20.9  8.3 pg/ml of vaginal fluid in saline controls or
CAI4 or triple mutant treated mice, respectively) (means 
standard errors of the means [SEM]). Overall, these findings sug-
gest that the proinflammatory potential of C. albicans in the va-
gina can be mediated, though to different magnitudes, by each of
the three proteins of the Sap1-3 subfamily. However, deletion of a
single gene, including SAP2, is compensated by the expression of
the other two genes. On the other hand, the lack of inflammatory
activity by the triple mutant also suggests that most of the inflam-
matory potential of the fungus is due, under our experimental
conditions, to the expression and activity of the SAP1, SAP2, and
SAP3 genes. This conclusion is also in agreement with the obser-
vations reported above that IL-1 production and neutrophil in-
flux in C. albicans-challenged mice are strongly inhibited by Abs
recognizing the three Sap (Fig. 3A and B).
It is known that vaginal inflammation is, in the mouse model,
largely uncoupled to the burden of intravaginal fungal growth (20,
22). Thus, we investigated whether this uncoupling was also veri-
fied in our CD1 mouse model, which is known to be relatively
resistant to vaginal infection but not, as shown above, to vaginal
inflammation caused by C. albicans. In these experiments, the
capacities of Pepstatin A and enzyme-inhibitory Abs to inhibit
C. albicans vaginal colonization, as reported in the rat model (9,
10), were tested by CFU enumeration and real-time imaging in
vivo technology. These experiments requested obvious protocol
variations (no vaginal wash at 24 h postchallenge and the first CFU
measurement was on day 2, when counts are more stable and
representative than on day 1) and the use of a luciferase-
expressing mutant strain of the fungus (already shown to cause
vaginal inflammation, similar to the strain used in the above-
described experiments) (23). Saline, nonimmune serum, and
noninhibitory HuCal nI, as well as fluconazole (FLZ), served as
negative- and positive-control treatments, respectively. Fungal
colonization was assayed on days 2 and 5 postchallenge. As shown
in Fig. 4A to E, none of the anti-Sap2 reagents caused a significant
reduction of the even-moderate intravaginal fungus burden, in-
dependent from the quantification protocol. Fluconazole exerted
a moderate inhibitory effect that was detectable on day 2 at a
statistically significant level only with the more sensitive biolumi-
nescence imaging technique (24) and was detectable with both
techniques on day 5. Determinations of intravaginal fungal
loads on day 2 after challenge were also performed with the
SAP-deleted mutants. We found that the fungal burden was mod-
erate (around 4 log CFU/g of vaginal tissue) and did not signifi-
cantly differ between the parental CAI4 strain and each single SAP
deletion mutant (data not shown).
Some mechanistic clues about Sap2-induced inflammation
at the vaginal level. Since (i) intracellular pattern recognition re-
ceptors (PRRs), including inflammasomes, play key roles in in-
flammation and anti-Candida defense (22, 25), and (ii) Sap2 (and
other Sap) is capable of activating NLRP3 inflammasome in hu-
man monocytes and other immune cells (12), we examined
whether the vaginal inflammation caused by Sap2 could also be
attributed to inflammasome activation. To this end, we analyzed
the cells of the vaginal exudate for the expression of activated
caspase-1 and IL-1 by using flow cytometry. As shown in Fig. 5A,
B, and C, the vaginal fluid harvested 24 h after Sap2 injection
contained numerous epithelial cells (expressing the CD326
marker) that were positive for both active caspase-1 and IL-1
proteins. In addition, both caspase-1 and IL-1 expression levels
in these cells were abolished by treatment with the caspase-1
inhibitor (IC-1) (Fig. 5B and C). This inhibitor did also almost
completely block the production of another inflammasome-
relevant cytokine, IL-18, in the vaginal fluid of Sap2-injected
mice (Fig. 5F).
The activation of caspase-1 and the induction of IL-1produc-
tion in the human vaginal epithelial cell line A-431 treated with
LPS plus ATP or Sap2 was also assayed by Western blotting (Fig.
5D). Both treatments induced caspase-1, and for both treatments
IC-1 caused inhibition of caspase-1 cleavage (more manifest,
however, with Sap2 than LPS under our conditions). Treatment of
cells with Pepstatin A almost completely abolished caspase-1 ac-
tivation (Fig. 5D) and IL-1 production (Fig. 5E) by Sap2-
stimulated vaginal epithelial cells. Together with the lack of
TNF- induction (see above and Fig. 1B), these findings are in-
dicative of inflammasome activation in Sap2-stimulated vaginal
epithelial cells, although they do not specify which specific inflam-
masome complex (NLRP1 or -3 or NLRC4) is activated. However,
it appears clear and in agreement with the markers of vaginal
inflammation shown in previous sections, that Sap2 requires en-
zymatic activity for this effect to occur.
DISCUSSION
Secretory aspartyl proteinases (Sap) have long been considered
key virulence traits of C. albicans, with rather strong experimental
and clinical evidence for a major role in vaginal candidiasis (1, 3).
However, the mechanisms by which this family of enzymes is in-
volved in vaginal disease have remained unclear. Sap are active
enzymes with a wide range of substrate specificities (26). Since
some of these substrates (e.g., complement, histatins, and
E-cadherin, and also Abs) play critical roles in both innate and
adaptive immune responses, Sap expression is thought to enable
the fungus to evade host immunity by enzymatic proteolysis of
one or more of the above factors (1, 3). Concurrently, studies in
well-established animal models and reconstituted human vaginal
epithelia have provided indirect clues for a role of some members
of the Sap family in facilitating fungus adherence and penetration
into epithelial tissues (27–30). Evidence gathered with the use of
anti-Sap Abs supports this proadherence role, although Sap are
not consistently expressed on the C. albicans cell surface (10). It is
relevant that anti-Sap Abs are not or are only erratically found
either in serum or vaginal fluid of colonized or even infected sub-
jects. To our knowledge, there has been no report on Abs capable
of neutralizing Sap enzymatic activity in any animal or human
organs or secretions. This is of particular importance for arguing
for or against the assumption that most, if not all, of Sap patho-
genic effects are mediated by their enzymatic activities.
In this study, we particularly focused on Sap2 as a potential
proinflammatory factor in vaginal candidiasis. Sap2 is a member
of the Sap family ofC. albicans that is dominantly expressed under
various in vitro and in vivo conditions, including experimental and
clinical candidiasis (1, 31, 32). The high expression levels of this
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FIG 4 Effects of immune serum, HuCal I, and Pepstatin A on vaginal colonization by C. albicans. Anesthetized mice under the pseudoestrus condition were
treated intravaginally 30 min before and again 30 min after challenge with gLUC59 (2 107 yeast cells/10l/mouse), with rabbit nonimmune or immune serum
and anti-tSap2, HuCal nI or HuCal I, Pepstatin A, or FLZ. At 2 and 5 days postchallenge, mice were treated intravaginally with 10l of coelenterazine (0.5 mg/ml)
and imaged with the IVIS-200TM imaging system under anesthesia with 2.5% isofluorane (A). Quantification of total photon emission from ROI was evaluated,
and the statistical significance was determined (B and D). #, P 0.05 for FLZ-treated versus saline-treated mice. Other groups of mice were treated as described
above, and at 2 and 5 days postchallenge the fungal burdens of vaginas were evaluated based on CFU measurements, and the statistical significance was
determined (C and E). Data are expressed as means SEM. #, P 0.05 for FLZ-treated versus saline-treated mice.
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protein in women affected by vaginal candidiasis, as well as the
capacity of anti-Sap2 Abs to confer some protection in animals
intravaginally challenged with this fungus, have constituted the
rationale for proposing a Sap2-based virosomal vaccine (11). This
vaccine was proved to be safe and immunogenic in a phase 1
clinical trial in Switzerland and is currently under consideration
for a combined anti-Candida vaccine by a U.S. company (Pevion,
NovaDigm). For progress in this area, it will be important to un-
derstand how Sap2 and other Sap, particularly those closely re-
lated to and serologically cross-reactive with Sap2, participate in
the pathogenesis of the disease and also which of the immune
responses to the vaccine is critical for protection. The literature
reported above, although of interest, does not address the immu-
nological aspects of Sap-related pathogenicity mechanisms and
the mechanisms of anti-Sap-mediated protection. In particular, it
is unclear which of the anti-Sap immune responses is effective for
controlling vaginal infection and whether this control is exerted
through inhibition of C. albicans growth or direct inhibition of
vaginal inflammation by the fungus, or both.
Although the capacity of some members of the Sap family to
cause inflammation has long been suspected, and proinflamma-
tory cytokine production upon Sap stimulation has been reported
from studies in in vitro systems (33), only recently has there been
a rather convincing demonstration that Sap2 and other Sap can
induce a classical inflammatory cascade mediated by NLRP3 in-
flammasome activation in cultured human monocytes and other
hematopoietic cells (12).
Based on the rationale above and the aforementioned in vitro
evidence, here we have studied the ability of Sap proteinases to
cause vaginal inflammation in vivo, focusing on Sap2 as a domi-
nant member of the family and a proposed protective vaccine
antigen. To this end, we used two recombinant Sap2 preparations:
the virosomal vaccine antigen, a truncated version lacking the first
N-terminal 76 amino acids, which is enzymatically inactive
(tSap2) (34), and a full-length, enzymatically active protein
(Sap2). These two proteins were directly injected into the mouse
vaginal cavity, and classical signs of local inflammation such as the
influx of PMN and the presence of a dominant proinflammatory
cytokine, such as IL-1, were monitored 24 h after Sap inocula-
tion. By this approach, we obtained the following original findings
in our vaginitis model: (i) Sap2, but not the vaccine antigen tSap2,
is capable of inducing inflammation in the vaginal cavity that is
substantially equivalent, in our model, to the inflammation in-
duced by early colonization with C. albicans; (ii) anti-Sap2 Abs
(cross-reactive with Sap1 and Sap3), as well as the Sap inhibitor
Pepstatin A, can neutralize Sap2-induced vaginal inflammation;
(iii) the same Abs and Pepstatin A equally inhibited C. albicans-
induced inflammation, provided that, for both findings ii and iii,
Abs, akin to Pepstatin A, were able to inhibit Sap enzymatic activ-
ity. We also show here for the first time that human-engineered
anti-Sap2 Abs, in the Fab format, can inhibit Sap enzyme activity
and inflammation and, by this mechanism, inhibit C. albicans-
induced vaginal inflammation. The apparent similar effects of
anti-Sap2 immune serum, Pepstatin A, and inhibitory HuCal I in
dampening C. albicans-induced vaginal inflammation also sug-
gest that sera from suitably immunized animals may indeed con-
tain Sap enzyme-inhibitory Abs.
Both Sap2-induced inflammatory signs, i.e., neutrophil influx
and cytokine production in the vaginal cavity, were obviously
variable in our model system. This may have been related not only
to the intrinsic variability of mouse responses but also to our own
approach of using unprotected Sap2 administration. We selected
this unconventional modality of Sap2 intravaginal administration
to avoid vaginal stimulation or irritation inevitably caused by ex-
ogenous materials added to Sap2 preparations, such as protein-
coating materials, gels, or preservants. Nonetheless, the evidence
for inflammatory processes occurring in the vaginal cavity follow-
ing Sap2 administration was consistent and reproducible when
measured both as PMN recruitment and cytokine production.
This proinflammatory activity did not appear to be mediated by
occasional pyrogenic contaminants, as our Sap2 preparations
were highly purified and essentially devoid of endotoxin. Impor-
tantly, the Sap2-specific binders capable of inhibiting both Sap2-
and C. albicans-induced inflammation were unable to affect LPS-
induced inflammation. This is also supported by the observation
that only those Abs capable of inhibiting Sap enzymatic activity
inhibited vaginal inflammation.
Our proposal that enzyme activity is critical for Sap2-induced
proinflammatory activity in the vaginal environment is clearly
supported by the inability of tSap2, which is devoid of enzymatic
activity, to cause vaginal inflammation, as well as by the potent
inhibition of inflammation caused by Pepstatin A, a well-known
inhibitor of aspartyl proteinase and Sap enzyme activity (35). This
would appear to make a rather remarkable and intriguing differ-
ence from Sap-induced inflammatory responses of human mono-
cytes (and other immune cells) that do not require Sap enzyme
activity (12). However, the different nature and functions of he-
mopoietic and vaginal epithelial cells should be considered.
Monocytes, macrophages, and dendritic cells are capable of
quickly internalizing particles or molecules by phagocytosis or
other pathways, while vaginal epithelial cells are coated by mucus
and a thick keratin-like material normally induced on the vaginal
mucosa by estrogen treatment (36). It is possible that enzymatic
activity is only required to hydrolyze the above-described material
and allow Sap penetration by clathrin-dependent mechanisms, as
has been suggested to occur in human monocytes (12). Notably,
keratin and keratin-like proteins are exquisitely sensitive to Sap
hydrolysis (6). It is also possible that vaginal inflammation is
FIG 5 Sap2-induced inflammasome activation in vaginal epithelial cells. Vaginal washes of mice treated for 24 h with saline, LPS (50 g/10 l/mouse),
or Sap2 (0.5 g/10 l/mouse) in the presence or absence of IC-1 were analyzed for the percentage of double-positive CD326/caspase-1 (A and B) and
CD326/IL-1 (A and C) cells, or for IL-18 production (F). Data are expressed as means SEM. *, P 0.05 for LPS- or Sap2-treated versus saline treated mice
and for IC-1 plus LPS- or Sap2-treated mice versus LPS- or Sap2-treated mice. For the gating strategy (A) of flow cytometry analysis, vaginal cells were gated on
CD326-positive epithelial cells (based on side light scatter and CD326 staining; R1), caspase-1-positive cells (based on side light scatter and caspase-1 staining;
R2), and IL-1-positive cells (based on side light scatter and IL-1 staining; R3). Hence, the logical “AND” operator was used: for R4 results from the intersection
between R1 and R2 and for R5 from the intersection between R1 and R3. For Western blotting, the A-431 cell line was untreated (NS) or treated for 2 h with LPS
(10 g/ml) plus ATP (5 mM) or Sap2 (20 g/ml) in the presence or absence of IC-1 or Pepstatin A. After incubation, cell lysates were analyzed by Western
blotting. Membranes were incubated with Abs to caspase-1 and actin. Caspase-1 results were normalized against those for actin (D). Culture supernatants were
collected and tested for IL-1 production (E). Data are expressed as means SEM. *, P 0.05 for LPS plus ATP or Sap2 treatment groups versus NS; #, P 0.05
for IC-1 plus LPS plus ATP or Sap2 or for Pepstatin A plus Sap2-treated versus LPS- or Sap2-treated.
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caused by Sap entering the epithelium and therein degrading an
intracellular protein, or simply the result of a Sap-mediated deg-
radation of one or more components of vaginal tissue or the vag-
inal microbiota. Inflammation could be contributed to, or en-
hanced by, cytokines or other mediators released not only by
epithelial cells, but also from PMNs and other inflammatory cells
recruited into the vaginal cavity. In fact, Sap2 is a PMN chemoat-
tractant (37, 38). Studies by Yano and collaborators and Peters
and collaborators (19, 20) have identified the calcium binding
proteins associated with the alarmin response as the epithelial fac-
tors responsible for the vaginal influx of PMN. In theory, Sap2
enzymatic activity could favor the release of these proinflamma-
tory mediators by the epithelial cells.
Importantly, our initial data on mechanisms of Sap2-induced
vaginitis call into play a similar activation of an inflammasome
sensor to that shown in previous studies with hematopoietic cells
(12, 18). Caspase-1 is expressed in murine vaginal epithelial cells
and a human vaginal epithelial cell line, with the consequent
cleavage of pro-IL-1 into the secreted cytokine. Inhibition of
caspase-1, therefore, causes the reduction of both IL-1 and an-
other inflammasome-relevant cytokine, IL-18. The role of IL-1
and inflammasome activation for neutrophil recruitment into the
vaginal cavity is further emphasized by the inhibition of PMN
influx via the blockade of the IL-1 receptor. Nonetheless, the full
elucidation of the mechanistic differences between hematopoietic
versus epithelial inflammasome activation in response to Sap2
awaits further comparative studies, which will include the use of
mice deficient in various inflammasome components.
A particularly important result of our study is that the early (24
h) vaginal inflammation caused by C. albicans is inhibited by the
same Abs and Pepstatin A that inhibit Sap2-induced inflamma-
tion. Neither anti-Sap2 immune serum nor HuCal I MAbs react
with the fungus itself and hence cannot inhibit adherence to or
entry into the vaginal epithelium. Therefore, the block of inflam-
mation cannot be explained by a reduced direct fungal contact.
Coupled with the observation that Pepstatin A is also capable of
strongly inhibiting PMN influx and IL-1 production during vag-
inal colonization by C. albicans, the data overall suggest that vag-
inal inflammation caused by this fungus in our mouse model is, at
least in part, mediated by Sap2 and/or the closely related, antigeni-
cally cross-reactive proteinases Sap1 and Sap3. The observation
that the triple SAP1 SAP2 SAP3 deletion mutant was unable to
cause vaginal inflammation would suggest that, under our exper-
imental conditions, vaginal inflammation caused by C. albicans is
predominantly due to members of the Sap1-3 subfamily. How-
ever, these data should be interpreted within the context and lim-
itations of our experimental model, which include a relatively
early stage of fungal establishment in the mouse vagina (24 h) and
the use of animals (CD1 mice) which are known to be relatively
resistant toC. albicans vaginal infection (but not, as shown here, to
vaginal inflammation). Therefore, we cannot exclude that mech-
anisms independent of Sap1-3 could cause C. albicans-mediated
vaginal inflammation. Other Sap are produced by the fungus dur-
ing the infection (1), and some of them can even prevail on Sap2
expression in other models of vaginal infection (39). They could
add to or replace Sap2, given that Sap enzymatic activity appears
to be the essential factor for inflammation to occur. In fact, Sap6
was also capable of inducing vaginal inflammation (see Fig. S2 in
the supplemental material).
No PRR is known for Sap, but it has been shown that these
proteins may enter the cell through clathrin-dependent pinocyto-
sis, hence acting as intracellular danger signals (12). Some authors
have suggested that inflammasome activation with its corollary of
IL-1 production is critical to induce a potent Th17 response,
with IL-17A and -F production in turn essential for control of
infection. Nonetheless, contrasting data have been reported on
this topic (23, 40, 41). In this context, it was logical to ask whether
inhibition of Sap2-induced inflammation by immune serum or
Pepstatin A had any effect on C. albicans vaginal growth and col-
onization. Our experiments showed that inhibition of Sap2-
induced vaginal inflammation had no consistent effect on vaginal
colonization, at least on its early, critical establishment stages, and
when the burden of fungal cells, like in our CD1 mouse model, is
not elevated (Fig. 4). Importantly, uncoupling of inflammation
and fungal growth has been reported in murine experimental
models (42), but not in other models of vaginal infection where
anti-Sap Abs and Pepstatin A have been shown to limit C. albicans
intravaginal growth (9). Nonetheless, pioneering work by Fidel’s
research group with experimental infections in women suggests
that the “inflammatory” mouse model may mimic inflammatory
signs of human candidal vaginitis (43). Overall, our data demon-
strate that Sap, in particular Sap2, or proteolytic products of Sap
activity are proinflammatory molecules which can be recognized
as danger signals by intracytoplasmic receptors and hence induce
a potent inflammatory cascade in vivo. In women affected by vag-
inal candidiasis, inflammatory signs are dominant, and the find-
ings illustrated in this study, linked to those of previous studies by
ourselves and others, point to a dominant role of Sap as direct or
indirect inducers of inflammation during C. albicans infection.
The demonstration that C. albicans-induced inflammation may
be inhibited by anti-Sap Abs corroborates the notion that a vac-
cine based on tSap2 antigen, hence inducing anti-Sap Abs, could
be efficacious in limiting or controlling vaginal inflammation.
This anti-inflammatory activity could usefully add to other
protection-relevant properties, such as the capacity of inhibiting
adherence and neutralizing other virulence properties expressed
by Sap in vitro and in other models of candidal vaginitis (3). It
should be noted that Abs inhibiting Sap2 enzyme activity have
been found in women during the phase 1 clinical trial of the viro-
somal tSap2 vaccine (unpublished data).
MATERIALS AND METHODS
Ethics statement. All animal experiments were performed in agreement
with the EU Directive 2010/2063, the European Convention for the Pro-
tection of Vertebrate Animals used for Experimental and Other Scientific
Purposes, and National Law 116/92. The protocol was approved by Peru-
gia University Ethics Committee for animal care and use (Comitato Uni-
versitario di Bioetica; permit no. 149/2009-B). All the animals were
housed in the animal facility of the University of Perugia (authorization
34/2003A).
Sap. Recombinant full-length Sap2 was expressed in Escherichia coli
BL21(pLysS) as a zymogen without the secretion header (39). Inclusion
bodies were dissolved in 8 M urea and renatured by dialysis with 10 mM
Tris (pH 8.0). Sap2 was autocatalytically activated by incubation at 37°C
for 30 min in 50 mM sodium citrate (pH 3.2) and buffer exchange over a
G25 Sephadex column (GE Healthcare) into 10 mM methylpiperazin
(pH 5.2). Highly purified active Sap2 was eluted at 30 ms/cm (pH 5.2)
from Q Sepharose FF (GE Healthcare) and was stored frozen. The in vitro
proteolytic activity of the resulting protein was comparable to that of
Pichia pastoris-expressed Sap2 when assessed as described by Wagener et
al. (44): it was Pepstatin A sensitive,90% inhibited by HuCal 10826 (see
below) at a stereochemical HuCal:Sap2 ratio of 2:1 when preincubated for
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30 min at neutral pH on ice, and it was insensitive to HuCal 10818 at a
ratio of 4:1 under identical conditions.
An E. coli recombinant truncated Sap2 (tSap2) preparation was pro-
duced and purified as described by Sandini et al. (34). While tSap2 was
enzymatically inactive (Fig. 1A), the anti-tSap2 Abs used throughout this
study efficiently recognized and bound to Sap2, and some of them inhib-
ited Sap2 enzymatic activity in vitro (see below). Where Sap2 has been
indicated in our text (with or without the t prefix), it means that the
indicated serum or MAb recognized with apparently similar reactivities
both Sap2 and tSap2. Both Sap2 and tSap2 were essentially endotoxin free
(0.05 EU/ml), as determined in a Limulus amebocyte gel assay (45).
Recombinant Sap1, Sap3, Sap5, Sap6, Sap9, and Sap10 were expressed in
Pichia pastoris as described previously. Proteins were purified from P. pas-
toris culture supernatants via anion-exchange chromatography, followed
by desalting by passage through a Sephadex G25 column, using 0.1 M
citrate buffer (pH 4.5; rSap1, rSap3, and rSap6) or pH 5.5 (rSap9 and
rSap10). rSap5 was purified via ultrafiltration (46, 47).
Human combinatorial Ab library (HuCal Abs 10818 and 10826).
The two recombinant HuCal Abs were produced by AbD-Serotec (Ger-
many) after screening a human combinatorial phage-display library
against tSap2. The HuCal Abs used in the experiment were bivalent Fab
mini-Abs containing a heavy chain C-terminal dHLX dimerization do-
main followed by Myc and His6 tags. Both Abs bind specifically to tSap2
protein, both in native and denatured form. However, one of them (Hu-
Cal 10826; here, HuCal I) inhibited Sap2 enzymatic activity when assayed
at a stereochemical HuCal I:Sap2 ratio of 2:1, whereas HuCal 10818 (re-
ferred to here as HuCal nl) bound to Sap2 but did not inhibit the enzy-
matic activity under the same condition. Neither HuCal I nor HuCal nI
bound to C. albicans.
Rabbit sera. A rabbit immune serum against tSap2 was generated by
ProSci Inc. (CA, USA) in New Zealand white rabbits. The standard pro-
tocol included repeated immunization with 0.1 mg tSap2, adjuvanted
with complete Freund’s adjuvant (CFA) for priming and incomplete
Freund’s adjuvant (IFA) for the subsequent 3 boosts, respectively. Blood
from the terminal bleeds from three immunized animals was pooled to
yield the immune serum. The nonimmune serum was derived from three
control rabbits that received PBS and adjuvant. The immune serum rec-
ognized with apparently similar efficiencies both the immunized antigen
(tSap2) and Sap2 antigen in a standard ELISA. No serum binding to C. al-
bicans in yeast or hyphal form was detected by immunofluorescence.
Candida albicans strains and culture. The origin and characteristics
of the highly virulentC. albicans strain used in this study (CA-6) have been
previously described (48). C. albicans 1398 carrying the ACT1p-gLUC59
fusion (gLUC59) was also used, as previously described (49). sap1,
sap2, andsap3 single deletion mutants (sap::hisG/sap::hisG::URA3::
hisG) and a sap1 sap2 sap3 triple deletion mutant (sap1::hisG/
sap1::hisGsap2::hisG/sap2::hisGsap3::hisG/sap3::hisG and the in-
tegration of the plasmid CIp10) were used and compared to the CIp10-
containing parental strain CAI4 (50–52). The cultures were maintained by
serial passages on Sabouraud agar plus chloramphenicol (50g/ml) (both
from Sigma-Aldrich). The yeast cells were harvested by suspending a sin-
gle colony in saline, washing twice, and counting in a hemocytometer, and
counts were adjusted to the desired concentration.
Mice. Female CD1 mice, obtained from Harlan Nossan Laboratories
(Milan, Italy), were purchased at 4 to 5 weeks of age. Mice were allowed to
rest for 1 week before the experiment; by that time the animals were
roughly 5 to 6 weeks old. Mice were used under specific-pathogen-free
conditions that included testing sentinels for unwanted infections; ac-
cording to the Federation of European, Laboratory Animal Science Asso-
ciation standards, no infections were detected.
Infection and treatment.Mice were maintained under a pseudoestrus
condition by subcutaneous (s.c.) injection of 0.2 mg of estradiol valerate
in 100 l of sesame oil (both from Sigma-Aldrich) 2 days prior to infec-
tion. Mice, anesthetized with 2.5 to 3.5 (vol/vol) isoflurane gas, were in-
jected into the vaginal lumen close to the cervix, 30 min before and again
30 min after treatment with LPS (50 g/10 l/mouse) or Sap2, tSap2, or
another Sap (all at 0.5 g/10 l/mouse), with rabbit nonimmune or im-
mune serum anti-tSap2 (both diluted 1:500 in saline, with injection vol-
umes of 10l/mouse), nonenzyme inhibitory HuCal nI, HuCal I strongly
inhibiting Sap2 enzyme activity (both at 0.36 ng/10 l/mouse), Pepstatin
A (1 g/10 l/mouse; Sigma-Aldrich), or a selective caspase-1 inhibitor,
Ac-YVAD-CMK (IC-1; 250 M/10 l/mouse; Dba Italia srl) (53). In se-
lected experiments anesthetized mice were injected into the vaginal lu-
men, 30 min before and again 30 min after challenge with C. albicans
(CA-6) or gLUC59 (both at 2 107 yeast cells/10 l/mouse), with rabbit
nonimmune or immune serum anti-tSap2 (both at a dilution of 1:500 in
saline/10l/mouse), HuCal nI or HuCal I (both at 0.36 ng/10l/mouse),
Pepstatin A (1 g/10 l/mouse), FLZ (60 g/10 l/mouse), or an antag-
onist of IL1beta receptor, anakinra (1, 10, or 100 M). To favor vaginal
contact and adsorption of the treatments, mice were held head down for
1 min following inoculation.
Monitoring of vaginalC. albicans burden. At days 2 and 5 postinfec-
tion, mice were treated with 10 l of coelenterazine (0.5 mg/ml in
methanol-H2O [1:10]; SynChem, OHM) in the vaginal lumen. Afterward,
mice were imaged with the IVIS-200TM imaging system (Xenogen Inc.)
under anesthesia with 2.5% isoflurane. Total photon emission from vag-
inal areas within the images (region of interest [ROI]) of each mouse was
quantified using the Living ImageR software package.
At days 2 and 5 postinfection, the fungal burdens of vaginas were also
evaluated by plating serial dilutions of organ homogenates onto yeast
extract-peptone-dextrose agar plus chloramphenicol (50 g/ml) (both
from Sigma-Aldrich) and counting the CFU.
Vaginal washes.Twenty-four hours postinfection, the vaginal lumens
were thoroughly washed with 150l of saline, given in three separate 50l
volumes. The washes were centrifuged, and the supernatants were col-
lected and tested for cytokine production. The total cellular fraction was
used for the flow cytometry analysis.
Flow cytometry analysis. Total cellular fractions obtained from vagi-
nal washes were fixed with 1.5% formalin, washed, allowed to react with a
fluorescein isothiocyanate-conjugated MAb to mouse Ly-6G (GR-1;
0.05 g/test; rat IgG2b; eBioscience, Inc., San Diego, CA) for 20 min at
room temperature (RT) in the dark. After incubation, cells were washed
twice with fluorescence buffer (FB), resuspended in 0.5 ml of FB, and then
analyzed by flow cytometry using a FACSCalibur system (Becton, Dick-
inson). Data are expressed as the percentage of GR-1-positive cells. In
selected experiments, cells were fixed with 1.5% formalin for 10 min at
RT, washed, and incubated with an allophycocyanin-labeled MAb to
mouse CD326 (0.05 g/test; rat IgG2b; eBioscience) for 20 min at RT in
the dark. After incubation, cells were washed twice with FB, permeabilized
with absolute methanol (500l/106 cells) for 10 min on ice, and incubated
with purified Abs to mouse cleaved caspase-1 or IL-1 (both goat second-
ary Abs, at a dilution 1:50; Santa Cruz Biotechnology, Santa Cruz, CA) for
20 min at RT followed by phycoerythrin-labeled conjugated affinity-
purified secondary Ab (dilution of 1:100; Chemicon Inc., Temecula, CA)
(54). Briefly, for the gating strategy of flow cytometry analysis, cells were
gated on CD326-positive epithelial cells (based on side light scatter and
CD326 staining; R1), cleaved caspase-1-positive cells (based on side light
scatter and cleaved caspase-1 staining; R2), and cleaved IL-1-positive
cells (based on side light scatter and cleaved IL-1 staining; R3). Hence,
the logical “AND” operator, which indicates whether both operands are
true, was used for R4 results from the intersection between R1 and R2, and
for R5 from the intersection between R1 and R3. Autofluorescence was
assessed by using untreated cells. Data are expressed as the percentage of
positive cells. Control staining of cells with irrelevant Abs was used to
obtain background fluorescence values.
Cytokine production. The supernatants from vaginal washes were
collected and tested for IL-1, IL-18, and TNF- levels by specific ELISAs
(all from eBioscience). Cytokine titers were calculated relative to standard
curves.
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A-431 vaginal cell line. The human A-431 vaginal epithelial cell line,
obtained from ATCC (LGC Standards, Milan, Italy) were grown in Dul-
becco’s modified Eagle’s medium plus 10% fetal calf serum as previously
described (55, 56). For stimulation experiments, A-431 cells were grown
in 6-well dishes, preincubated in serum-free medium for 2 h, and stimu-
lated for 2 h at 37°C plus 5% CO2 with LPS (10 g/ml) and ATP (5 mM)
or Sap2 (20 g/ml) in the presence or absence of IC-1 (25 M) (12) or
Pepstatin A (1 g/ml).
Western blot analysis. After stimulation, A-431 cells were recovered
by adding trypsin-EDTA (BioWhittaker), washing, and lysing with mam-
malian protein extraction reagent in the presence of protease and phos-
phatase inhibitors (all obtained from Pierce, Rockford, IL). Protein con-
centrations were determined with a bicinchoninic acid protein assay
reagent kit (Pierce). The lysates (60g) were separated by sodium dodecyl
sulfate–10% PAGE and transferred to a nitrocellulose membrane (Pierce)
for 1 h at 100 V in a blotting system (Bio-Rad, Hercules, CA). The mem-
branes were incubated overnight with polyclonal Abs to human cleaved
caspase-1 (goat) and cleaved IL-1 (goat) (both diluted 1:200; Santa Cruz
Biotechnology) in blocking buffer. Detection was achieved with the ap-
propriate secondary Ab coupled to horseradish peroxidase, followed by
use of a chemilucent trial kit (Chemicon Inc.). Immunoblotting with
rabbit polyclonal Ab to actin (dilution of 1:200; Santa Cruz Biotechnol-
ogy) was used as an internal loading control. Immunoreactive bands were
visualized and quantified by using a Chemidoc instrument (Bio-Rad). In
particular, quantitative analysis of the region of interest was performed
using the Fiji Is Just ImageJ program.
Determination of Sap2 and tSap2 activities. Bovine serum albumin
(BSA; 1% [wt/vol]) was incubated in citrate buffer (0.1 M, pH 3.2, at
37°C) for 15 min in the presence or absence of Sap2 or tSap2 (both at
100 g/ml) with or without Pepstatin A (100 g/ml). After incubation,
BSA hydrolysis, performed by SDS-PAGE, was observed in the presence of
Sap2 but not tSap2 (see Fig. S1A in the supplemental material).
Statistical analysis. The in vivo results illustrated in bar graphs in the
figures are reported as means SEM from 3 to 5 different mice in 3 to 4
separate experiments. For data reported as dot plot graphs, the numbers
of analyzed mice for each treatment are indicated in the figure. Quantita-
tive variables were tested for normal distribution and compared by means
of Student’s two-tailed t test. A two-tailed test of significance at a P level of
0.05 was used to determine statistical significance.
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ADDENDUM
While our manuscript was being revised in preparation for submission, a
paper appeared in mBio that described a role for NLRP3 inflammasome
and hyphae-associated aspartyl proteinases in murine vaginal candidiasis
[see V. M. Bruno, A. C. Shetty, J. Yano, P. L. Fidel, Jr., M. C. Noverr, and
B. M. Peters, mBio 6(2):e00182-15, 2015, http://dx.doi.org/10.1128/
mBio.00182-15].
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